Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Milos, Pesek"'
Autor:
Lucie Benesova, Renata Ptackova, Tereza Halkova, Anastasiya Semyakina, Martin Svaton, Ondrej Fiala, Milos Pesek, Marek Minarik
Publikováno v:
Pathology and Oncology Research, Vol 28 (2022)
Background: Observation of anticancer therapy effect by monitoring of minimal residual disease (MRD) is becoming an important tool in management of non-small cell lung cancer (NSCLC). The approach is based on periodic detection and quantification of
Externí odkaz:
https://doaj.org/article/089f2946a5c14fe4914df4dad2fe7b16
Autor:
Kristian Brat, Monika Bratova, Jana Skrickova, Magda Barinova, Karolina Hurdalkova, Milos Pesek, Libor Havel, Leona Koubkova, Michal Hrnciarik, Jana Krejci, Ondrej Fischer, Milada Zemanova, Helena Coupkova, Martin Svaton
Publikováno v:
Thoracic Cancer, Vol 11, Iss 11, Pp 3346-3356 (2020)
Background Data regarding real‐life effectiveness of any treatment may improve clinical decision‐making. The aim of this study was to evaluate real‐life effectiveness of tyrosin‐kinase inhibitors, bevacizumab and pemetrexed as first‐line tr
Externí odkaz:
https://doaj.org/article/cbc351e845594ab6848729e0cc8a090b
Autor:
Milada Zemanova, Marketa Cernovska, Libor Havel, Tomas Bartek, Sarka Lukesova, Jitka Jakesova, Jaroslav Vanasek, Pavel Reiterer, Juraj Kultan, Igor Andrasina, Lenka Siskova, Leona Koubkova, Jana Skrickova, Frantisek Salajka, Milos Pesek, Petr Klepetko, Juraj Beniak, Harald Fricke, Pavla Kadlecova, Roman P. Korolkiewicz, Marek Hraska, Jirina Bartunkova, Radek Spisek
Publikováno v:
Cancer Treatment and Research Communications, Vol 28, Iss , Pp 100427- (2021)
Purpose: To investigate the efficacy and safety of an active cellular immunotherapy (DCVAC/LuCa) and chemotherapy in patients with stage IV non-small cell lung cancer (NSCLC). Patients and Methods: SLU01 was a multicenter, open-label, parallel-group,
Externí odkaz:
https://doaj.org/article/df2a1c8d1d664d14ac381beb83a7255a
Autor:
ONDREJ FIALA, JAN BAXA, MARTIN SVATON, LUCIE BENESOVA, RENATA PTACKOVA, TEREZA HALKOVA, MAREK MINARIK, PETR HOSEK, MARCELA BURESOVA, JINDRICH FINEK, JIRI FERDA, MILOS PESEK
Publikováno v:
Cancer Genomics - Proteomics. 19:270-281
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::db82bd4c2d614a36ca4d8500be6f29d4
https://doi.org/10.21873/cgp.20319
https://doi.org/10.21873/cgp.20319
Autor:
Marcela Buresova, Lucie Benesova, Marek Minarik, Renata Ptackova, Tereza Halkova, Petr Hosek, Jan Baxa, Milos Pesek, Martin Svaton, Ondrej Fiala
Publikováno v:
Journal of Cancer. 14(1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a1378d68f543fe8995a92e51d46b9fe
https://pubmed.ncbi.nlm.nih.gov/36605490
https://pubmed.ncbi.nlm.nih.gov/36605490
Autor:
Ondrej Fiala, Milos Pesek, Jana Skrickova, Vitezslav Kolek, Frantisek Salajka, Marcela Tomiskova, Monika Satankova, Juraj Kultan, Jana Kuliskova, Martin Svaton, Michal Hrnciarik, Karel Hejduk, Renata Chloupkova, Ondrej Topolcan, Helena Hornychova, Marketa Nova, Ales Ryska, Jindrich Finek
Publikováno v:
Tumor Biology, Vol 39 (2017)
Pemetrexed is an antifolate cytostatic agent targeting several folate-dependent enzymatic pathways, widely used in the treatment of locally advanced or metastatic stage non-small cell lung cancer. Aside from the non-squamous histology, there is still
Externí odkaz:
https://doaj.org/article/a10b69b60ee9430d88da3e92872c1cd6
Autor:
Ondrej, Fiala, Jan, Baxa, Martin, Svaton, Lucie, Benesova, Renata, Ptackova, Tereza, Halkova, Marek, Minarik, Petr, Hosek, Marcela, Buresova, Jindrich, Finek, Jiri, Ferda, Milos, Pesek
Publikováno v:
Cancer Genomics Proteomics
Background/Aim: Circulating tumour DNA (ctDNA) represents an emerging biomarker in non-small cell lung cancer (NSCLC). We focused on the combination of ctDNA and positron emission tomography/computed tomography (PET/CT) in the follow-up monitoring of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f2cdad7f836a4c8033cac0913dad5ec2
https://pubmed.ncbi.nlm.nih.gov/35181593
https://pubmed.ncbi.nlm.nih.gov/35181593
Autor:
Martin, Svaton, Ondrej, Fiala, Gabriela, Krakorova, Jiri, Blazek, Karolina, Hurdalkova, Magda, Barinova, Petr, Mukensnabl, Milos, Pesek
Publikováno v:
Oncology Letters
While erlotinib is primarily administered to patients with non-small cell lung cancer with sensitizing epidermal growth factor receptor (EGFR) mutations, it is also prescribed to patients with wild type (wt) EGFR in higher lines of treatment. However
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2baadbe8e65ce55a1d1722a96de8ac60
https://pubmed.ncbi.nlm.nih.gov/32724380
https://pubmed.ncbi.nlm.nih.gov/32724380
Autor:
Jan, Baxa, Tana, Matouskova, Jaroslav, Ludvik, Martin, Sedlmair, Thomas, Flohr, Bernhard, Schmidt, Jiri, Bejcek, Milos, Pesek, Jiri, Ferda
Publikováno v:
Anticancer research. 38(7)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::65fe3fa2baf571acfb4a4ecd4e0e2e5f
https://pubmed.ncbi.nlm.nih.gov/29970540
https://pubmed.ncbi.nlm.nih.gov/29970540
Autor:
Martin, Svaton, Ondrej, Fiala, Milos, Pesek, Zbynek, Bortlicek, Marek, Minarik, Lucie, Benesova, Ondrej, Topolcan
Publikováno v:
Anticancer research. 36(3)
The prognostic and predictive value of Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation in non-small cell lung cancer (NSCLC) is not well established. The present study aimed at the elucidation of the role of KRAS mutation in prediction of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::72f924a3870178105d159742837f7fae
https://pubmed.ncbi.nlm.nih.gov/26977001
https://pubmed.ncbi.nlm.nih.gov/26977001